CervoMed Q4/FY2025 net loss widens to $27M; cash runway ~6 months; Phase 3 DLB trial pending financing

CervoMed Inc.

FY2025 net loss $27.0M vs $16.2M; cash $20.9M (down from $38.9M), sufficient for ~6 months.
FDA alignment obtained for planned Phase 3 DLB trial; initiation in H2 2026 subject to funding.
Selected 50mg TID neflamapimod dose for Phase 3; additional data to be presented at AD/PD 2026.
Topline data expected H2 2026 from Phase 2a RAS and nfvPPA trials; ALS trial start by YE 2026.
Grant revenue fell to $4.0M from $9.7M due to RewinD-LB completion; R&D spend rose to $21.8M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CervoMed Inc. reported financial results for the fourth quarter ended December 31, 2025.

Period: the fourth quarter ended December 31, 2025
Result: reported results

Exact text from the filing

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided corporate updates.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CervoMed Inc. reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided corporate updates.

View on SEC.gov

Browse all earnings releases →

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-008611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.